Trial intelligence / Profile preview

Capmatinib versus docetaxel in previously treated MET exon 14 skipping non-small cell lung cancer

NL-OMON52922Phase 3Active, not recruiting

Sponsor

Novartis

Start

Jun 2021

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1